$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000156459022032555 Filed on September 28, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$11.04M	$9.881M	$41.34M
YoY Change	4.86%	-4.39%	1.62%
Cost Of Revenue	$4.369M	$4.248M	$16.42M
YoY Change	7.27%	7.71%	5.14%
Gross Profit	$6.668M	$5.633M	$24.93M
YoY Change	3.35%	-11.86%	-0.57%
Gross Profit Margin	60.41%	57.01%	60.29%
Selling, General & Admin	$6.820M	$6.249M	$24.38M
YoY Change	13.1%	213.55%	36.89%
% of Gross Profit	102.28%	110.94%	97.8%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$368.0K	$460.0K	$1.543M
YoY Change	10.51%	13.86%	13.37%
% of Gross Profit	5.52%	8.17%	6.19%
Operating Expenses	$8.281M	$7.844M	$30.27M
YoY Change	11.23%	130.5%	30.47%
Operating Profit	-$1.613M	-$2.211M	-$5.340M
YoY Change	62.44%	-174.0%	-385.41%
Interest Expense	-$4.000K	$3.000K	-$15.00K
YoY Change	-71.43%	-142.86%	-46.43%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.544M	-$2.210M	-$1.615M
YoY Change	-176.89%	-147.37%	-123.07%
Income Tax	$0.00	$107.0K	$107.0K
% Of Pretax Income
Net Earnings	-$1.558M	-$2.365M	-$2.009M
YoY Change	-180.35%	-150.46%	-129.16%
Net Earnings / Revenue	-14.12%	-23.93%	-4.86%
Basic Earnings Per Share	-$0.22		-$0.29
Diluted Earnings Per Share	-$0.22	-$340.1K	-$0.29
COMMON SHARES
Basic Shares Outstanding	7.032M		6.945M
Diluted Shares Outstanding	6.983M		6.945M

Balance Sheet

Concept	2022 Q3	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.951M
YoY Change	-44.58%
Cash & Equivalents	$4.951M	$6.794M
Short-Term Investments
Other Short-Term Assets	$2.166M
YoY Change	-5.46%
Inventory	$1.842M	$1.748M
Prepaid Expenses
Receivables	$4.686M
Other Receivables	$1.761M
Total Short-Term Assets	$15.41M	$16.82M
YoY Change	-28.06%	-23.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.482M	$8.217M
YoY Change	22.57%	25.37%
Goodwill
YoY Change
Intangibles	$1.195M	$1.201M
YoY Change	-2.05%	-2.12%
Long-Term Investments
YoY Change
Other Assets	$630.0K	$523.0K
YoY Change	-2.93%	-11.51%
Total Long-Term Assets	$11.42M	$11.13M
YoY Change	14.73%	15.64%
TOTAL ASSETS
Total Short-Term Assets	$15.41M	$16.82M
Total Long-Term Assets	$11.42M	$11.13M
Total Assets	$26.83M	$27.94M
YoY Change	-14.48%	-11.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.831M	$1.347M
YoY Change	7.83%	22.9%
Accrued Expenses	$5.822M
YoY Change	9.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$41.00K	$40.00K
YoY Change	10.81%	-98.67%
Total Short-Term Liabilities	$8.163M	$7.691M
YoY Change	8.19%	-20.42%
LONG-TERM LIABILITIES
Long-Term Debt	$3.000K	$14.00K
YoY Change	-93.18%	-73.08%
Other Long-Term Liabilities	$114.0K	$106.0K
YoY Change	-88.93%	-19.08%
Total Long-Term Liabilities	$1.053M	$1.132M
YoY Change	-1.96%	3.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.163M	$7.691M
Total Long-Term Liabilities	$1.053M	$1.132M
Total Liabilities	$9.216M	$8.823M
YoY Change	6.93%	-17.96%
SHAREHOLDERS EQUITY
Retained Earnings	$3.242M	$4.800M
YoY Change		-29.51%
Common Stock	$14.26M	$14.21M
YoY Change		0.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.61M
YoY Change
Total Liabilities & Shareholders Equity	$26.83M	$27.94M
YoY Change	-14.48%	-11.47%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$1.558M	-$2.365M	-$2.009M
YoY Change	-180.35%	-150.46%	-129.16%
Depreciation, Depletion And Amortization	$368.0K	$460.0K	$1.543M
YoY Change	10.51%	13.86%	13.37%
Cash From Operating Activities	-$1.271M		-$4.000K
YoY Change	280.54%		-100.29%
INVESTING ACTIVITIES
Capital Expenditures	$624.0K		$3.190M
YoY Change	-9.83%		22.93%
Acquisitions
YoY Change
Other Investing Activities	$51.00K		$10.00K
YoY Change	920.0%		-76.74%
Cash From Investing Activities	-$562.0K		-$3.128M
YoY Change	-18.2%		22.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$10.00K		$36.00K
YoY Change	25.0%		2.86%
Cash From Financing Activities	-10.00K		-36.00K
YoY Change	25.0%		2.86%
NET CHANGE
Cash From Operating Activities	-1.271M		-4.000K
Cash From Investing Activities	-562.0K		-3.128M
Cash From Financing Activities	-10.00K		-36.00K
Net Change In Cash	-1.843M		-3.168M
YoY Change	79.11%		159.25%
FREE CASH FLOW
Cash From Operating Activities	-$1.271M		-$4.000K
Capital Expenditures	$624.0K		$3.190M
Free Cash Flow	-$1.895M		-$3.194M
YoY Change	84.7%		159.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5340000
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	OH
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
CY2022	dei	City Area Code CityAreaCode	770
CY2022	dei	Local Phone Number LocalPhoneNumber	933-7000
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7031603
CY2021Q4	dei	Entity Public Float EntityPublicFloat	7946583
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.00
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.99
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-36000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3168000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11184000
CY2022	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	370000
CY2021	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	1179000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	141000
CY2022	ssy	Interest Paid Received Net InterestPaidReceivedNet	5000
CY2021	ssy	Interest Paid Received Net InterestPaidReceivedNet	-1000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	293000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	177000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7067000
CY2021	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	37000
CY2022	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	2000
CY2021	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	2000
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y25D
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2021Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	72000
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37000
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	52000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	511000
CY2021	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	7000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	34000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1179000
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0153
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-126000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-143000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3128000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2552000
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6700000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6700000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1470000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1076000
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	188000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6794000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9962000
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4624000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1347000
CY2021Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4189000
CY2022Q2	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2022Q2	us-gaap	Change In Accounting Principle Accounting Standards Update Immaterial Effect ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect	true
CY2022	us-gaap	Change In Accounting Principle Accounting Standards Update Transition Option Elected Extensible List ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201409Member
CY2022	ssy	Age Of Participants To Take Monthly Pension Benefits One AgeOfParticipantsToTakeMonthlyPensionBenefitsOne	P65Y
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2022Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2021Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M3D
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M28D
CY2021Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M28D
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Entity File Number EntityFileNumber	1-12607
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Auditor Name AuditorName	Cherry Bekaert, LLP
CY2022	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2022	dei	Auditor Firm AuditorFirmId	677
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2911000
CY2021Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	3069000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2021Q2	us-gaap	Assets Assets	31564000
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2021Q2	us-gaap	Inventory Net InventoryNet	1890000
CY2022Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	1761000
CY2021Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	3586000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1888000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2314000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	16815000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	21941000
CY2022Q2	us-gaap	Land Land	582000
CY2021Q2	us-gaap	Land Land	582000
CY2022Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	7381000
CY2021Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	6361000
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	15957000
CY2021Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13937000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23920000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20880000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15703000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14326000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8217000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6554000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1201000
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1227000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1251000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	591000
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1096000
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	40000
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	3009000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1520000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1866000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2021Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1966000
CY2022Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	519000
CY2021Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	437000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	403000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1313000
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	888000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7691000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9665000
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14000
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52000
CY2022Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	86000
CY2021Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	31000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	875000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69000
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106000
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	131000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1132000
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1089000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2021Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6954000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6954000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6924000
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6924000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3478000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	3463000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10736000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10700000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4800000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6809000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-162000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20810000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27943000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31564000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40685000
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19006000
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	13797000
CY2022	us-gaap	Supplies Expense SuppliesExpense	1276000
CY2021	us-gaap	Supplies Expense SuppliesExpense	989000
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	4345000
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	4029000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	552000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	553000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1543000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1361000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1871000
CY2022	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	720000
CY2021	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	4880000
CY2022	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	3010000
CY2021	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	264000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-28000
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	10000
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	13000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1615000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	6937000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-47000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6890000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1741000
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6907000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13743000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6890000
CY2021	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	177000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20810000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2022	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	268000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2022	us-gaap	Profit Loss ProfitLoss	-2009000
CY2021	us-gaap	Profit Loss ProfitLoss	6890000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1543000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1361000
CY2022	ssy	Forgiveness Of Paycheck Protection Plan Loans And Accrued Interest ForgivenessOfPaycheckProtectionPlanLoansAndAccruedInterest	3010000
CY2021	ssy	Forgiveness Of Paycheck Protection Plan Loans And Accrued Interest ForgivenessOfPaycheckProtectionPlanLoansAndAccruedInterest	264000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	13000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	435000
CY2022	ssy	Increase Decrease In Employee Retention Credits Receivable IncreaseDecreaseInEmployeeRetentionCreditsReceivable	-1825000
CY2021	ssy	Increase Decrease In Employee Retention Credits Receivable IncreaseDecreaseInEmployeeRetentionCreditsReceivable	3586000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-565000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	668000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	403000
CY2022	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	82000
CY2021	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	-4095000
CY2022	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	634000
CY2021	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	555000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1365000
CY2022	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	51000
CY2021	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	43000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3190000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2595000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	36000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	35000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-35000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1222000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9962000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9962000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. BUSINESS OPERATIONS</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink Health Systems, Inc., through subsidiaries (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”), owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><span style="font-weight:normal;">The Healthcare Services business is composed of:</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary which owns and operates Trace Regional Medical Center (“Trace”) which is comprised of a 49 licensed-bed acute care hospital, located in Houston, Mississippi. Our Medical Center also includes an 18-bed geriatric psychiatry unit (“GPU”), and a 66-bed extended care and rehabilitation center. This facility focuses primarily on senior healthcare services.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">subsidiary, SunLink Health Systems Technology (“SHST Technology”), which provides information technology (“IT”) to outside customers and to SunLink subsidiaries. </span><span style="font-family:Calibri;font-size:11pt;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi</span>. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</span> </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy business, which is composed of four operational areas:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in rural markets at two locations in Louisiana</span>. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:9.07%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#212529;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">COVID-19 Pandemic and CARES Act Funding</span></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:8pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We have continued to monitor the impact on our operations of the COVID-19 pandemic and its aftermath and have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance have been subject to frequent changes and at times have been unclear. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:8pt;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nevertheless, as in many healthcare environments, we have experienced </span><span style="color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disruption of our operations, </span><span style="color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine. We believe the effect of the COVID-19 pandemic and certain public and certain governmental responses to it have negatively affected our last </span><span style="color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten</span><span style="color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> quarter’s results. </span></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:8pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2020, we began receiving allotments of COVID-19 vaccine and have vaccinated patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate. Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination. The Company and its subsidiaries are currently developing and will implement plans to vaccinate employees to the extent required by the final rules of CMS. The Company believes the vaccine mandates have resulted in the loss of staff, including clinical staff, and together with the current state of the labor market, have negatively affected the Company’s ability to maintain the current levels of service. </p> <p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:6.67%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Healthcare Segment business, we have experienced material reductions in demand and net revenues due to the COVID-19 pandemic and its aftermath. There continues to be reduced current demand for certain hospital services and for extended care, rehabilitation center and nursing home admissions and clinic visits. The availability and cost of medical supplies have adversely affected our Healthcare businesses and we continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees accompanied by an increase in the levels of salaries, wages and benefits have occurred, and, despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at reduced capacity, and until these referral sources resume operating at full capacity, we believe the COVID-19 pandemic will have continuing to effects on the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Extended care facilities and rehabilitation centers, nursing homes and other customers of our Institutional Pharmacy services continue to be adversely affected by the COVID-19 pandemic. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic and its aftermath also has and continues to negatively affected our supply processes and costs generally.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:8pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;text-indent:6.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Healthcare and Pharmacy segments have received approximately $6,173 in general and targeted Provider Relief Funds ("PRF") during the period April 1, 2020 through June 30, 2022 under the CARES Act, which was enacted in March 2020 in response to the COVID-19 pandemic. The PRF distributions have been accounted for as government grants, and a total of $5,652 have been recognized since April l, 2020 as other income under the gain contingency recognition method.</p> <p style="margin-bottom:8pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;text-indent:6.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the quarter ended June 30, 2020, our Healthcare and Pharmacy segments received $3,234 in Paycheck Protection Plan (“PPP”) loans provided under the CARES Act. These loans were forgivable upon compliance with conditions specified under the PPP loan program. As of June 30, 2022, all our PPP loans have been forgiven.</p> <p style="Background-color:#FFFFFF;margin-bottom:7pt;margin-top:5pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">The Taxpayer Certainty and Disaster Tax Relief Act of 2020, enacted December 27, 2020, made a number of changes to employer retention tax credits previously made available under the CARES Act, including modifying and extending the Employee Retention Credit ("ERC") for the six calendar months ending June 30, 2021. As a result of such legislation, the Company qualified for ERC for the first and second calendar quarters of 2021 due to the decrease in its gross receipts and has applied for ERC of $3,586 through amended quarterly payroll tax filings for the applicable quarters. Through the date of this filing, the Company has received $1,803 of ERC which we applied for. We continue to monitor compliance with the terms and conditions of the ERC and PPP programs and developing interpretations and enforcement of the ERC and PPP program rules and the regulations. </p> <p style="margin-bottom:12pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;text-indent:0%;color:#1B1B1B;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="margin-left:36pt;"/><span style="font-family:Times New Roman;color:#000000;">PRF distributions are subject to Federal audits and Single Audits not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19 and for "Lost Revenues" as defined by the department of “HHS”. We continue to monitor compliance with the terms and conditions of the PRF and developing interpretations and enforcement of PRF rules and regulations, as well as the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the PRF received may be impacted, and we may have to return the unutilized portion of those funds, if any, in the future.</span></p> <p style="margin-bottom:12pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">The Company is unable to determine the extent to which the COVID-19 pandemic and its aftermath will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. </p> <p style="margin-bottom:12pt;margin-top:0pt;margin-left:0.32%;margin-right:0.19%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nature and extent of the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continuing </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect of the COVID-19 pandemic</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and its aftermath </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our balance sheet and results of operations will depend on the severity and length of the pandemic</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or to evolving strains of COVID-19</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any further </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government actions to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">address</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the pandemic's </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continuing </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect; regulatory changes in response to the pandemic, especially those that affect our hospital, extended care, rehabilitation center, nursing home, clinics, and our pharmacy operations; existing and potential government assistance that may be provided; and the requirements of PRF receipts, including our ability to retain such PRF received.</span></p>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2022	ssy	Employee Retention Credit Qualified Wages Limited Per Employee Per Quarter EmployeeRetentionCreditQualifiedWagesLimitedPerEmployeePerQuarter	3586000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management Estimates<span style="font-weight:normal;font-style:normal;"> —The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates made by management involve reserves for adjustments to net patient service revenues, evaluation of the recoverability of assets, including accounts receivable and intangible assets, and the assessment of litigation and contingencies, including income taxes and related tax asset valuation allowances, all as discussed in more detail in the remainder of these notes to the consolidated financial statements. Actual results could differ materially from these estimates.</span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk<span style="font-weight:normal;font-style:normal;"> —SunLink’s Healthcare Services segment subsidiaries grant unsecured credit to their patients, most of who reside in the service area of the subsidiaries’ facilities and are insured under third-party agreements. Medicare and </span></p> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:normal;">Medicaid patient accounts represent SunLink’s only significant concentrations of credit risk. For SunLink’s Healthcare Services segment, Medicare net revenues were approximately </span>57<span style="font-weight:normal;font-style:normal;">% and </span><span style="font-weight:normal;font-style:normal;">52</span><span style="font-weight:normal;font-style:normal;">% of net revenues for the years ended June 30, 20</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;"> and 20</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;">1</span><span style="font-weight:normal;font-style:normal;">, respectively. For SunLink’s Healthcare Services segment, Medicaid was approximately </span>32<span style="font-weight:normal;font-style:normal;">% and </span>31<span style="font-weight:normal;font-style:normal;">% net revenues for the years ended June 30, 20</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;"> and 20</span><span style="font-weight:normal;font-style:normal;">2</span><span style="font-weight:normal;font-style:normal;">1</span><span style="font-weight:normal;font-style:normal;">, respectively. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink’s Pharmacy segment subsidiary grants unsecured credit to individual customers and institutional customers. Individual customers primarily are insured under third-party agreements, including Medicare and Medicaid, while the institutional customers are granted credit according to their determined credit risk. Medicare receivables were approximately 30% and 21% of the Pharmacy segment’s receivables at June 30, 2022 and 2021, respectively, while Medicaid receivables were approximately 17% and 24% of the Pharmacy segment receivable at June 30, 2022 and 2021, respectively. </p>
CY2022Q2	us-gaap	Cash Cash	6794000
CY2022Q2	ssy	Cash Deposits In Excess Of Federally Insured Limits CashDepositsInExcessOfFederallyInsuredLimits	5995000
CY2022	ssy	Overnight Repurchase Agreements Collateralized By Government Backed Securities OvernightRepurchaseAgreementsCollateralizedByGovernmentBackedSecurities	1.02
CY2022	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	Depreciation is recognized over the estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2022	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2022	us-gaap	Depreciation Depreciation	1517000
CY2021	us-gaap	Depreciation Depreciation	1334000
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	361000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	42000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	352000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	15000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	330000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	174000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000
CY2022Q2	ssy	Long Term Debt Maturities Repayments Of Principal In Year Six And After Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndAfterYearSix	0
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	24000
CY2021	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	191000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-287000
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-47000
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2021	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-47000
CY2022Q2	us-gaap	Change In Accounting Principle Accounting Standards Update Adoption Date ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate	2018-07-01
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0
CY2022Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1228000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	57000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40685000
CY2022	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	33000
CY2021	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	69000
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Three LongTermDebtContractualCommitmentsForInterestInYearThree	0
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Four LongTermDebtContractualCommitmentsForInterestInYearFour	0
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Five LongTermDebtContractualCommitmentsForInterestInYearFive	0
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2021Q2	us-gaap	Inventory Net InventoryNet	1890000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	468000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	514000
CY2022	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	82000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	552000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	553000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7000
CY2022	ssy	Finance Lease Cost FinanceLeaseCost	41000
CY2021	ssy	Finance Lease Cost FinanceLeaseCost	43000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1251000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2022Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	101000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	471000
CY2022	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	5000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	36000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	370000
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0103
CY2022Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1209000
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	54000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	21000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	0
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	0
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	0
CY2022Q2	ssy	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafterFive	0
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21000
CY2022Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	54000
CY2021Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	89000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	54000
CY2021Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	3061000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	40000
CY2021Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3009000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14000
CY2021Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	52000
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	40000
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Next Twelve Months LongTermDebtContractualCommitmentsForInterestInNextTwelveMonths	3000
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	14000
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Two LongTermDebtContractualCommitmentsForInterestInYearTwo	0
CY2022Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Six And After Year Six LongTermDebtContractualCommitmentsForInterestInYearSixAndAfterYearSix	0
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	54000
CY2022Q2	ssy	Long Term Debt Contractual Commitments LongTermDebtContractualCommitments	3000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	480000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.35
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.39
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	410000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2022	ssy	Share Based Compensation Arrangement By Share Based Payments Award Options Exercised In Period Range Of Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsExercisedInPeriodRangeOfExercisePrice	1.67
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	380000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.31
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	410000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.34
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	380000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.31
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70000
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	594000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	594000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-339000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-339000
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	177000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	177000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-162000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-162000
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	268000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	106000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	38000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	63000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	69000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7275000
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5856000
CY2022Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	-122000
CY2021Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	-98000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	255000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	117000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	237000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	268000
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-35000
CY2021Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	263000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	32000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	113000
CY2022Q2	ssy	Deferred Tax Asset Provider Relief Funds DeferredTaxAssetProviderReliefFunds	126000
CY2021Q2	ssy	Deferred Tax Asset Provider Relief Funds DeferredTaxAssetProviderReliefFunds	0
CY2022Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	291000
CY2021Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	0
CY2022Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	292000
CY2021Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	0
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	83000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	181000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7850000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7919000
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2021Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-339000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	968000
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	48000
CY2022	ssy	Income Tax Reconciliation Prior Year True Ups Associated With Cares Act Receipts IncomeTaxReconciliationPriorYearTrueUpsAssociatedWithCARESActReceipts	0
CY2021	ssy	Income Tax Reconciliation Prior Year True Ups Associated With Cares Act Receipts IncomeTaxReconciliationPriorYearTrueUpsAssociatedWithCARESActReceipts	-587000
CY2022	ssy	Income Tax Reconciliation Permanent Differences Relating To Cares Act Receipts IncomeTaxReconciliationPermanentDifferencesRelatingToCARESActReceipts	0
CY2021	ssy	Income Tax Reconciliation Permanent Differences Relating To Cares Act Receipts IncomeTaxReconciliationPermanentDifferencesRelatingToCARESActReceipts	-56000
CY2022	ssy	Income Tax Reconciliation Permanent Differences Relating To Paycheck Protection Plan Loan Forgiveness IncomeTaxReconciliationPermanentDifferencesRelatingToPaycheckProtectionPlanLoanForgiveness	-632000
CY2021	ssy	Income Tax Reconciliation Permanent Differences Relating To Paycheck Protection Plan Loan Forgiveness IncomeTaxReconciliationPermanentDifferencesRelatingToPaycheckProtectionPlanLoanForgiveness	0
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	77000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	62000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	47000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7919000
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	21653000
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	21653000
CY2022	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2023 through fiscal 2038
CY2021	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2022	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2022Q2	ssy	Plans Assets Invested In Cash And Short Term Investments PlansAssetsInvestedInCashAndShortTermInvestments	0.47
CY2022Q2	ssy	Plans Assets Invested In Equity Investments PlansAssetsInvestedInEquityInvestments	0.39
CY2022Q2	ssy	Plans Assets Invested In Fixed Income Investments PlansAssetsInvestedInFixedIncomeInvestments	0.14
CY2022	ssy	Expected Return On Investment ExpectedReturnOnInvestment	0.04
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	44000
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	51000
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	149000
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	57000
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	64000
CY2022Q2	ssy	Plan Expected To Pay In Pension Benefits Through Three Years PlanExpectedToPayInPensionBenefitsThroughThreeYears	358000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2022Q2	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	100000
CY2021Q2	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	100000
CY2022	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2021Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1966000
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0280
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0260
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2021Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1535000
CY2020Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1574000
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	42000
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	40000
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	378000
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	51000
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	27000
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	28000
CY2022Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1172000
CY2021Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1535000
CY2021Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1080000
CY2020Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	923000
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-112000
CY2021	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	85000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	27000
CY2021	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	28000
CY2022Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1041000
CY2021Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1080000
CY2022Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-131000
CY2021Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-455000
CY2022	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	24000
CY2021	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	293000
CY2022Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-107000
CY2021Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-162000
CY2022Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-107000
CY2021Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-162000
CY2022Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	24000
CY2021Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	293000
CY2022Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-131000
CY2021Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-455000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92000
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5340000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1543000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3190000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40685000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1871000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1361000
CY2021Q2	us-gaap	Assets Assets	31564000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2595000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	6937000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6907000
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.00
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989000
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.99
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-47000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6907000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6890000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6907000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6907000
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	82000

Files In Submission

Name	View Source	Status
0001564590-22-032555-index-headers.html	Edgar Link	pending
0001564590-22-032555-index.html	Edgar Link	pending
0001564590-22-032555.txt	Edgar Link	pending
0001564590-22-032555-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-10k_20220630.htm	Edgar Link	pending
ssy-20220630.xsd	Edgar Link	pending
ssy-ex211_6.htm	Edgar Link	pending
ssy-ex231_10.htm	Edgar Link	pending
ssy-ex311_9.htm	Edgar Link	pending
ssy-ex312_7.htm	Edgar Link	pending
ssy-ex321_11.htm	Edgar Link	pending
ssy-ex322_8.htm	Edgar Link	pending
ssy-20220630_def.xml	Edgar Link	unprocessable
ssy-20220630_lab.xml	Edgar Link	unprocessable
ssy-20220630_pre.xml	Edgar Link	unprocessable
ssy-10k_20220630_htm.xml	Edgar Link	completed
ssy-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2022 Q3 Form 10-K Financial Statement

#000156459022032555 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2022 Q3 Form 10-K Financial Statement

#000156459022032555 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy